The design of a series of thromboxane receptor antagonists based on ch
lorophenyl)sulfonyl}amino]ethyl)benzenepropanoic acid (1) is described
. Addition of an arylmethyl group at the 5-position of 1 gave exceptio
nally potent agents in vitro and in vivo, with 13a (UK-147,535) giving
complete blockade of the TxA(2) receptor for greater than 12 hours in
dogs, following all oral dose of 0.1 mg/kg. (C) 1998 Elsevier Science
Ltd. All rights reserved.